Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease

Charles T. Quinn; Marie J. Stuart; Karen Kesler; Kenneth I. Ataga; Winfred C. Wang; Lori Styles; Kim Smith-Whitley; Ted Wun; Ashok Raj; Lewis L. Hsu; Suba Krishnan; Frans A. Kuypers; Yamaja Setty; Seungshin Rhee; Nigel S. Key; George R. Buchanan

doi:10.1111/j.1365-2141.2011.08827.x

Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease

Charles T. Quinn, Marie J. Stuart, Karen Kesler, Kenneth I. Ataga, Winfred C. Wang, Lori Styles, Kim Smith-Whitley, Ted Wun, Ashok Raj, Lewis L. Hsu, Suba Krishnan, Frans A. Kuypers, Yamaja Setty, Seungshin Rhee, Nigel S. Key, George R. Buchanan

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

Tapered oral dexamethasone for acute chest syndrome (ACS) in sickle cell anaemia was studied using a novel ACS assessment tool and investigational biomarkers. Twelve participants were randomized (mean age 17·3years) before early study termination. Dexamethasone decreased duration of hospitalization for ACS by 20·8h compared to placebo (P=0·024). Rebound pain occurred in both groups (3 dexamethasone versus 1 placebo). Overall, dexamethasone decreased the leucocyte activation biomarker, sL-selectin; however, participants with rebound pain had higher sL-selectin within 24h of treatment (dexamethasone or placebo). This ACS assessment tool was feasibly applied, and sL-selectin is a promising biomarker of ACS therapy.

Original language	English (US)
Pages (from-to)	263-267
Number of pages	5
Journal	British Journal of Haematology
Volume	155
Issue number	2
DOIs	https://doi.org/10.1111/j.1365-2141.2011.08827.x
State	Published - Oct 2011

Keywords

Acute chest syndrome
Biomarkers
Corticosteroid
L-selectin
Sickle cell disease

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/j.1365-2141.2011.08827.x

Cite this

Quinn, C. T., Stuart, M. J., Kesler, K., Ataga, K. I., Wang, W. C., Styles, L., Smith-Whitley, K., Wun, T., Raj, A., Hsu, L. L., Krishnan, S., Kuypers, F. A., Setty, Y., Rhee, S., Key, N. S., & Buchanan, G. R. (2011). Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. British Journal of Haematology, 155(2), 263-267. https://doi.org/10.1111/j.1365-2141.2011.08827.x

Quinn, CT, Stuart, MJ, Kesler, K, Ataga, KI, Wang, WC, Styles, L, Smith-Whitley, K, Wun, T, Raj, A, Hsu, LL, Krishnan, S, Kuypers, FA, Setty, Y, Rhee, S, Key, NS & Buchanan, GR 2011, 'Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease', British Journal of Haematology, vol. 155, no. 2, pp. 263-267. https://doi.org/10.1111/j.1365-2141.2011.08827.x

@article{2a961642bca74ed2ba7f34f630626703,

title = "Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease",

abstract = "Tapered oral dexamethasone for acute chest syndrome (ACS) in sickle cell anaemia was studied using a novel ACS assessment tool and investigational biomarkers. Twelve participants were randomized (mean age 17·3years) before early study termination. Dexamethasone decreased duration of hospitalization for ACS by 20·8h compared to placebo (P=0·024). Rebound pain occurred in both groups (3 dexamethasone versus 1 placebo). Overall, dexamethasone decreased the leucocyte activation biomarker, sL-selectin; however, participants with rebound pain had higher sL-selectin within 24h of treatment (dexamethasone or placebo). This ACS assessment tool was feasibly applied, and sL-selectin is a promising biomarker of ACS therapy.",

keywords = "Acute chest syndrome, Biomarkers, Corticosteroid, L-selectin, Sickle cell disease",

author = "Quinn, {Charles T.} and Stuart, {Marie J.} and Karen Kesler and Ataga, {Kenneth I.} and Wang, {Winfred C.} and Lori Styles and Kim Smith-Whitley and Ted Wun and Ashok Raj and Hsu, {Lewis L.} and Suba Krishnan and Kuypers, {Frans A.} and Yamaja Setty and Seungshin Rhee and Key, {Nigel S.} and Buchanan, {George R.}",

year = "2011",

month = oct,

doi = "10.1111/j.1365-2141.2011.08827.x",

language = "English (US)",

volume = "155",

pages = "263--267",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease

AU - Quinn, Charles T.

AU - Stuart, Marie J.

AU - Kesler, Karen

AU - Ataga, Kenneth I.

AU - Wang, Winfred C.

AU - Styles, Lori

AU - Smith-Whitley, Kim

AU - Wun, Ted

AU - Raj, Ashok

AU - Hsu, Lewis L.

AU - Krishnan, Suba

AU - Kuypers, Frans A.

AU - Setty, Yamaja

AU - Rhee, Seungshin

AU - Key, Nigel S.

AU - Buchanan, George R.

PY - 2011/10

Y1 - 2011/10

N2 - Tapered oral dexamethasone for acute chest syndrome (ACS) in sickle cell anaemia was studied using a novel ACS assessment tool and investigational biomarkers. Twelve participants were randomized (mean age 17·3years) before early study termination. Dexamethasone decreased duration of hospitalization for ACS by 20·8h compared to placebo (P=0·024). Rebound pain occurred in both groups (3 dexamethasone versus 1 placebo). Overall, dexamethasone decreased the leucocyte activation biomarker, sL-selectin; however, participants with rebound pain had higher sL-selectin within 24h of treatment (dexamethasone or placebo). This ACS assessment tool was feasibly applied, and sL-selectin is a promising biomarker of ACS therapy.

AB - Tapered oral dexamethasone for acute chest syndrome (ACS) in sickle cell anaemia was studied using a novel ACS assessment tool and investigational biomarkers. Twelve participants were randomized (mean age 17·3years) before early study termination. Dexamethasone decreased duration of hospitalization for ACS by 20·8h compared to placebo (P=0·024). Rebound pain occurred in both groups (3 dexamethasone versus 1 placebo). Overall, dexamethasone decreased the leucocyte activation biomarker, sL-selectin; however, participants with rebound pain had higher sL-selectin within 24h of treatment (dexamethasone or placebo). This ACS assessment tool was feasibly applied, and sL-selectin is a promising biomarker of ACS therapy.

KW - Acute chest syndrome

KW - Biomarkers

KW - Corticosteroid

KW - L-selectin

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=80053570618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053570618&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2011.08827.x

DO - 10.1111/j.1365-2141.2011.08827.x

M3 - Article

C2 - 21848879

AN - SCOPUS:80053570618

SN - 0007-1048

VL - 155

SP - 263

EP - 267

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 2

ER -

Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this